Share on StockTwits

IDEXX Laboratories (NASDAQ:IDXX) was downgraded by equities researchers at Northcoast Research to a “sell” rating in a research report issued on Wednesday.

Several other analysts have also recently commented on the stock. Analysts at Piper Jaffray raised their price target on shares of IDEXX Laboratories from $125.00 to $126.00 in a research note on Monday, July 28th. Separately, analysts at Zacks reiterated a “neutral” rating on shares of IDEXX Laboratories in a research note on Wednesday, July 16th. They now have a $139.00 price target on the stock. Finally, analysts at Canaccord Genuity upgraded shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a research note on Tuesday, June 24th. They now have a $148.00 price target on the stock, up previously from $116.00. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and an average target price of $136.60.

IDEXX Laboratories (NASDAQ:IDXX) traded down 2.83% during mid-day trading on Wednesday, hitting $125.14. The stock had a trading volume of 211,136 shares. IDEXX Laboratories has a one year low of $92.09 and a one year high of $140.00. The stock’s 50-day moving average is $130. and its 200-day moving average is $126.7. The company has a market cap of $6.291 billion and a P/E ratio of 35.14.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings results on Friday, July 25th. The company reported $1.10 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.05 by $0.05. The company had revenue of $390.00 million for the quarter, compared to the consensus estimate of $385.20 million. During the same quarter last year, the company posted $0.99 earnings per share. IDEXX Laboratories’s revenue was up 10.6% compared to the same quarter last year. On average, analysts predict that IDEXX Laboratories will post $3.85 earnings per share for the current fiscal year.

In other IDEXX Laboratories news, Director M Anne Szostak purchased 2,000 shares of the company’s stock in a transaction dated Wednesday, August 13th. The stock was purchased at an average cost of $127.03 per share, with a total value of $254,060.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link.

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services primarily for the companion animal veterinary, livestock and poultry, water testing and dairy markets.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.